We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BWXT a Buy as Nuclear Growth Meets Execution and Valuation Risk?
Read MoreHide Full Article
Key Takeaways
BWXT's nuclear expansion is backed by more than $1.4 billion in naval contracts and a growing backlog.
BWXT raised its 2026 revenue outlook to $3.80 billion, with adjusted EPS projected at $4.70-$4.80.
BWXT's 27.10X forward P/E, margin pressure and fourth-quarter earnings concentration support a cautious view.
BWX Technologies, Inc. (BWXT - Free Report) is expanding across defense and commercial nuclear markets, but the investment decision is less straightforward than the growth narrative alone suggests. The company is carrying a large backlog, raising guidance and adding capacity as demand builds.
Investors still have to weigh that momentum against a valuation near BWXT’s own five-year norm and an outlook that requires dependable second-half execution. The question is whether the growth profile justifies buying now or whether waiting for more operating evidence is prudent.
BWXT Growth Is Broadening Across Nuclear Markets
BWXT’s opportunity set spans naval propulsion, uranium enrichment, commercial nuclear equipment and lifecycle services. In May 2026, the company received more than $1.4 billion of U.S. Naval Nuclear Propulsion Program contracts, including nearly $1.29 billion for long-lead materials and $165 million for Ford-class carrier work.
The company is also advancing a planned defense uranium-enrichment facility tied to a previously announced $1.5 billion National Nuclear Security Administration contract. BWXT began Nuclear Regulatory Commission engagement in April 2026, with a license application expected in the first quarter of 2027. Curtiss-Wright Corporation (CW - Free Report) offers a useful industry comparison because its Naval & Power segment serves both U.S. naval nuclear programs and commercial nuclear customers.
BWXT Valuation Sits Near Its Five-Year Median
BWXT trades at 27.10X forward 12-month earnings, almost in line with its five-year median of 27.46X. That is below the Zacks sub-industry multiple of 31.38X and the Zacks sector multiple of 28.51X.
The stock is therefore not priced near the high end of its historical range, but the current multiple does not indicate an obvious bargain either. The valuation still assumes that BWXT can convert nuclear demand and backlog into durable earnings growth. Huntington Ingalls Industries, Inc. (HII - Free Report) , whose Newport News Shipbuilding division builds nuclear-powered aircraft carriers and submarines, underscores the long-cycle nature of the naval nuclear market that supports part of BWXT’s opportunity base.
BWXT Guidance Supports the Fundamental Case
Management raised its 2026 outlook after the first half. BWXT now expects revenues of about $3.80 billion, adjusted earnings of $4.70-$4.80 per share, adjusted EBITDA of $662-$672 million and free cash flow of $345-$360 million.
The higher outlook strengthens the fundamental case because the revisions span earnings, cash flow and operating profit. Yet, the guidance also keeps the focus on delivery. Approximately 55% of second-half 2026 earnings are expected in the fourth quarter, increasing the importance of execution late in the year.
BWXT Still Faces Margin and Award-Timing Risks
Commercial Operations is expanding quickly, but growth is capital intensive. BWXT lowered 2026 Commercial adjusted EBITDA margin guidance to about 13% from about 14% as it invests in U.S. capacity, the Precision Components Group acquisition and Canada.
New awards are another source of uncertainty. Management sees a credible opportunity to secure at least one new-build nuclear equipment order before year-end 2026, but customer, procurement and regulatory timing can shift. Government Operations can also experience quarterly variability from contract mix and favorable adjustments, so backlog should not be treated as guaranteed near-term earnings.
BWXT Signals Favor a Balanced Investment View
BWXT’s growth story is supported by diversified nuclear demand, higher guidance and a valuation below its sub-industry average. At the same time, a forward P/E near the company’s five-year median leaves less room for execution shortfalls than a deeply discounted valuation would.
The supported Neutral stance remains appropriate, balancing favorable nuclear demand and reasonable relative valuation against margin pressure, award timing and the concentration of second-half earnings in the fourth quarter.
BWXT Stock Price Movement
In the past six months, BWX Technologies shares have fallen 41.7% compared with the industry’s decline of 16.8%.
View the Zacks #1 Rank List
Image: Shutterstock
Is BWXT a Buy as Nuclear Growth Meets Execution and Valuation Risk?
Key Takeaways
BWX Technologies, Inc. (BWXT - Free Report) is expanding across defense and commercial nuclear markets, but the investment decision is less straightforward than the growth narrative alone suggests. The company is carrying a large backlog, raising guidance and adding capacity as demand builds.
Investors still have to weigh that momentum against a valuation near BWXT’s own five-year norm and an outlook that requires dependable second-half execution. The question is whether the growth profile justifies buying now or whether waiting for more operating evidence is prudent.
BWXT Growth Is Broadening Across Nuclear Markets
BWXT’s opportunity set spans naval propulsion, uranium enrichment, commercial nuclear equipment and lifecycle services. In May 2026, the company received more than $1.4 billion of U.S. Naval Nuclear Propulsion Program contracts, including nearly $1.29 billion for long-lead materials and $165 million for Ford-class carrier work.
The company is also advancing a planned defense uranium-enrichment facility tied to a previously announced $1.5 billion National Nuclear Security Administration contract. BWXT began Nuclear Regulatory Commission engagement in April 2026, with a license application expected in the first quarter of 2027. Curtiss-Wright Corporation (CW - Free Report) offers a useful industry comparison because its Naval & Power segment serves both U.S. naval nuclear programs and commercial nuclear customers.
BWXT Valuation Sits Near Its Five-Year Median
BWXT trades at 27.10X forward 12-month earnings, almost in line with its five-year median of 27.46X. That is below the Zacks sub-industry multiple of 31.38X and the Zacks sector multiple of 28.51X.
The stock is therefore not priced near the high end of its historical range, but the current multiple does not indicate an obvious bargain either. The valuation still assumes that BWXT can convert nuclear demand and backlog into durable earnings growth. Huntington Ingalls Industries, Inc. (HII - Free Report) , whose Newport News Shipbuilding division builds nuclear-powered aircraft carriers and submarines, underscores the long-cycle nature of the naval nuclear market that supports part of BWXT’s opportunity base.
BWXT Guidance Supports the Fundamental Case
Management raised its 2026 outlook after the first half. BWXT now expects revenues of about $3.80 billion, adjusted earnings of $4.70-$4.80 per share, adjusted EBITDA of $662-$672 million and free cash flow of $345-$360 million.
The higher outlook strengthens the fundamental case because the revisions span earnings, cash flow and operating profit. Yet, the guidance also keeps the focus on delivery. Approximately 55% of second-half 2026 earnings are expected in the fourth quarter, increasing the importance of execution late in the year.
BWXT Still Faces Margin and Award-Timing Risks
Commercial Operations is expanding quickly, but growth is capital intensive. BWXT lowered 2026 Commercial adjusted EBITDA margin guidance to about 13% from about 14% as it invests in U.S. capacity, the Precision Components Group acquisition and Canada.
New awards are another source of uncertainty. Management sees a credible opportunity to secure at least one new-build nuclear equipment order before year-end 2026, but customer, procurement and regulatory timing can shift. Government Operations can also experience quarterly variability from contract mix and favorable adjustments, so backlog should not be treated as guaranteed near-term earnings.
BWXT Signals Favor a Balanced Investment View
BWXT’s growth story is supported by diversified nuclear demand, higher guidance and a valuation below its sub-industry average. At the same time, a forward P/E near the company’s five-year median leaves less room for execution shortfalls than a deeply discounted valuation would.
The supported Neutral stance remains appropriate, balancing favorable nuclear demand and reasonable relative valuation against margin pressure, award timing and the concentration of second-half earnings in the fourth quarter.
BWXT Stock Price Movement
In the past six months, BWX Technologies shares have fallen 41.7% compared with the industry’s decline of 16.8%.
Image Source: Bigstock
BWXT’s Zacks Rank
BWX Technologies currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.